Jenkoo
@Jenkoool
Followers
254
Following
3K
Statuses
1K
This is how I want to hear #AVCT BoD talking publicly
“Given the importance of our Miracle trial as a pivotal registration clinical trial, we were extremely pleased to receive detailed follow up from the FDA regarding our IND amendment to enable the trial," commented Walter Klemp, $MBRX CEO. For more:
4
1
13
@ElkHunter78 I don’t think so, but I’ve come to realise over the years my opinion is often wrong. 🤭 Surely with what they hold in IP, and the DX sale; a placing can be avoided. I would be extremely disappointed in bod if that was the case. Even if it is shaped as SH longer term value.
1
1
9
@AndrewDigby3 Doing my best not to look at the SP 😣/😂 Since my first investment, feels like: Short term - pain, Medium term - more pain Long term - TBC 🙏🏻 Desperately hope we have a transformational Q3 post P1 results.
0
0
0
@Tom_The_Bomb__ @asininitybeyond Can’t get the NASDAQ indecisiveness out of my mind. I can’t help but feel they prefer either: 1) Partner to raise cash & stay on AIM Or 2) Sale of #AVCT Every way I look at it, dual listing would be a cert value driver. It’s a no brainier isn’t it? 🤯🤷♂️ or am I missing something
2
0
7
@Share_Talk If #AVCT were to raise any where near this SP, it would completely undo all of the progress made by the new BOD & cast serious doubt on their commercial acumen. I suspect they have bigger plans at play, but only time will tell. Personally I am confident CC will deliver. 🙏🏻
1
0
22
@SeanDentBsc @coughlin582 Absolutely. Here’s to hoping that PL bring actual value to #AVCT and shareholders …. unlike others 😳 I’m sure CC and team would have stipulated certain requirements and desires before making the appointment. Another small step forward today whilst we await some ‘big news’
1
0
16
@boy_cellar Personal view is unchanged…. Patience is required here. The co. have said long term value will be gained by holding onto the IP for as long as possible and not making smaller deals early. I still think a deal will be made by end of 2025 & DX sale by end of Q2. Good luck to LTH’s
1
0
19
Have to say I’m really impressed with Grok. Really useful, detailed and up to date.
0
0
1
Christina Coughlin of Avacta 23/08/24: “never doubt that a small group of thoughtful, committed citizens can change the world. Indeed it is the only thing that ever has” 😊 #AVCT
In this episode of the R&D Spotlight Series we look at some of the new science ongoing on at Avacta, specifically around our second asset that will go into the clinic, AVA6103. We also discuss how AI is being leveraged to optimise patient populations #AVCT
1
7
47
@Ian07594592 Based on the increasing CoS (positive data + pipeline & indication optionally), I expect the commercial side ‘will’ follow (albeit not as fast as PI’s would like). DX sale kicks #AVCT into a new era of commercial activity IMO. BoD going from strength to strength.
1
1
10
@asininitybeyond @AndrewDigby3 Agree AAB. I’m not against paying in shares, just a shame we couldn’t harness some momentum. Interestingly regarding NASDAQ listing ‘further updates provided in the coming months’ - I think they want P1b data before listing application & global specialist biotech investors 👍🏻
0
0
0
@AndrewDigby3 I think the bod is just splitting the asset ahead of the sale. The DX division needs splitting away regardless, so doing it in advance of the TO speeds things up once a deal is signed. Possibly makes it more attractive too to new bidders.
0
0
0
@Livinginthesurf Dilution is a risk. To ignore it & play it down is rampy & ignorant imo. I have never sold an #avct share, so unable to ‘buy back’ My portfolio is 100% avacta. I do not want this price to go down any further than the ridiculous price we already sit at.
2
0
11